Search
forLearn
5 / 801 resultslearn sh-Polypeptide-7
learn ACETYL TETRAPEPTIDE-2
learn glutamic acid
learn acetyl methionine
Research
5 / 64 results
research Inactivation of autophagy leads to changes in sebaceous gland morphology and function
Autophagy is crucial for normal sebaceous gland function and sebum composition.
research 1329 Transglutaminase 2 deficiency leads to lipid accumulation and reduced autophagy in SZ95 sebocytes
Lack of TG2 increases fat storage and lowers cell cleanup in skin oil cells.
research Autophagy protects murine preputial glands against premature aging, and controls their sebum phospholipid and pheromone profile
Autophagy prevents early aging and maintains lipid and pheromone balance in mouse glands.
research Autophagy protects murine preputial glands against premature aging, and controls their sebum phospholipid and pheromone profile
Autophagy helps mouse glands stay healthy, prevents early aging, and maintains their oil and scent production.
research TLR3 Activation Stimulates Autophagy Gene Expression in Keratinocytes
Activating TLR3 boosts autophagy gene expression in skin cells.
Community Join
5 / 1000+ resultscommunity CRISPR treatment for AGA on the horizon after approval for blood disorders
CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community Best Treatment In The Pipeline?
New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community What is preventing GT20029 from being the cure to androgenetic hair loss?
GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.